FDA approves new indication for Prolia® (Denosumab) for the treatment of bone loss in men with osteoporosis at high risk for fracture
A new indication for Prolia® approved...
20 September 2012 | By Amgen
A new indication for Prolia® approved...
List view / Grid view
Sean E. Harper is the Executive Vice President, Research and Development at Amgen. Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen’s Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies.
Dr. Harper served as vice president of Global Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.
Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.
A new indication for Prolia® approved...
20 September 2012 | By Amgen
A new indication for Prolia® approved...
Amgen announced a decision to stop the ganitumab Phase 3…
8 August 2012 | By Amgen
Amgen announced a decision to stop the ganitumab Phase 3 GAMMA trial...
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
The FDA cannot approve the application in its present form...
26 April 2012 | By Amgen
The FDA cannot approve the application in its present form...
Amgen and KAI Pharmaceuticals have announced an agreement under which…
10 April 2012 | By Amgen
Amgen and KAI Pharmaceuticals have announced an agreement under which Amgen will acquire KAI...
The start of sclerostin antibody Phase 3 clinical trial program…
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
Robust AMG 145 Phase 2 program expected to deliver results…
25 March 2012 | By Amgen
Robust AMG 145 Phase 2 program expected to deliver results in 2012...
"Mike brings broad experience and immense expertise to his new…
14 February 2012 | By Amgen
"Mike brings broad experience and immense expertise to his new role..."
Amgen to discuss the data from the sBLA for XGEVA®…
8 February 2012 | By Amgen
Amgen to discuss the data from the sBLA for XGEVA® (denosumab)...